Recovery of OATP1B Activity After Living Kidney Transplantation in Patients with End-Stage Renal Disease

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2019 Feb 28

PMID 30809779

Citations 3

Authors

Yosuke Suzuki

Hiroyuki Ono

Ryota Tanaka

Fuminori Sato

Yuhki Sato

Keiko Ohno

Hiromitsu Mimata

Hiroki Itoh

Affiliations

Soon will be listed here.

Abstract

Purpose: Recently, several studies have shown that renal failure decreases the metabolic clearance of drugs and the transportation capability of some drug transporters. However, whether organic anion transporting polypeptide (OATP)1B activities decrease in renal failure remains unknown. In this study, we measured plasma concentrations of coproporphyrin-I (CP-I), a specific endogenous OATP1B probe, in patients with end stage renal disease before and after living kidney transplantation and evaluated the effect of renal function on OATP1B activity.

Methods: This prospective study recruited 13 patients with end-stage renal disease. Plasma CP-I concentrations were measured before and 7, 14, 30 and 90 days after living kidney transplantation.

Results: Plasma CP-I concentrations decreased over time after living kidney transplantation and showed significant difference on day 90 compared with before living kidney transplantation [1.12 ± 0.59 vs 0.65 ± 0.27 ng/mL, p < 0.05 (95% CI of difference - 0.927, -0.013)]. A significant negative correlation was observed between estimated glomerular filtration rate and plasma CP-I concentration (r = -0.30, p < 0.05), suggesting recovery of OATP1B activity with improvement in renal function.

Conclusions: OATP1B activity may decrease in renal failure and dose adjustment of OATP1B substrates may be needed in patients with renal failure.

Citing Articles

Utility of Biomarker-Informed Drug Interaction Evaluation in Drug Development and Regulatory Decision Making.

Ishiguro A, Kusuhara H, Kimoto E, Miyoshi S, Mizuno K, Hoshino M Clin Pharmacol Ther. 2024; 117(2):398-402.

PMID: 39246046 PMC: 11739733. DOI: 10.1002/cpt.3436.

Relationship of plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease.

Ono H, Tanaka R, Suzuki Y, Oda A, Sato H, Tatsuta R Clin Transl Sci. 2024; 17(2):e13731.

PMID: 38564661 PMC: 10844757. DOI: 10.1111/cts.13731.

Relationship of hemoglobin level and plasma coproporphyrin-I concentrations as an endogenous probe for phenotyping OATP1B.

Suzuki Y, Sasamoto Y, Koyama T, Yoshijima C, Oda A, Nakatochi M Clin Transl Sci. 2021; 14(4):1403-1411.

PMID: 33650309 PMC: 8301560. DOI: 10.1111/cts.12996.

Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.

Suzuki Y, Sasamoto Y, Koyama T, Yoshijima C, Nakatochi M, Kubo M Clin Transl Sci. 2020; 14(1):382-388.

PMID: 32961019 PMC: 7877856. DOI: 10.1111/cts.12889.

References

Leblond F, Giroux L, Villeneuve J, Pichette V . Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000; 28(11):1317-20. View

Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V . Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001; 12(2):326-332. DOI: 10.1681/ASN.V122326. View

Guevin C, Michaud J, Naud J, Leblond F, Pichette V . Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002; 137(7):1039-46. PMC: 1573574. DOI: 10.1038/sj.bjp.0704951. View

Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T . Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6):554-65. DOI: 10.1016/S0009-9236(03)00060-2. View

Rege B, Krieg R, Gao N, Sarkar M . Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm Res. 2003; 20(10):1600-6. DOI: 10.1023/a:1026135317578. View

Sun H, Huang Y, Frassetto L, Benet L . Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004; 32(11):1239-46. DOI: 10.1124/dmd.104.000521. View

Niemi M, Kivisto K, Hofmann U, Schwab M, Eichelbaum M, Fromm M . Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005; 59(5):602-4. PMC: 1884844. DOI: 10.1111/j.1365-2125.2005.02354.x. View

Launay-Vacher V, Izzedine H, Deray G . Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005; 101(1):9-17. DOI: 10.1016/j.ijcard.2004.04.005. View

Niemi M, Backman J, Kajosaari L, Leathart J, Neuvonen M, Daly A . Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77(6):468-78. DOI: 10.1016/j.clpt.2005.01.018. View

10.

Lemahieu W, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y . Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005; 5(9):2236-43. DOI: 10.1111/j.1600-6143.2005.01005.x. View

11.

Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H . Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78(4):330-41. DOI: 10.1016/j.clpt.2005.06.013. View

12.

Chung J, Cho J, Yu K, Kim J, Oh D, Jung H . Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005; 78(4):342-50. DOI: 10.1016/j.clpt.2005.07.003. View

13.

Hanada K, Ogawa R, Son K, Sasaki Y, Kikkawa A, Ichihara S . Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol. 2006; 103(4):p179-86. DOI: 10.1159/000092919. View

14.

Pasanen M, Neuvonen M, Neuvonen P, Niemi M . SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16(12):873-9. DOI: 10.1097/01.fpc.0000230416.82349.90. View

15.

Pasanen M, FREDRIKSON H, Neuvonen P, Niemi M . Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82(6):726-33. DOI: 10.1038/sj.clpt.6100220. View

16.

Naud J, Michaud J, Leblond F, Lefrancois S, Bonnardeaux A, Pichette V . Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2007; 36(1):124-8. DOI: 10.1124/dmd.107.018192. View

17.

Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y . Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2008; 36(4):663-9. DOI: 10.1124/dmd.107.017814. View

18.

Michaud J, Nolin T, Naud J, Dani M, Lafrance J, Leblond F . Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci. 2008; 108(2):157-63. DOI: 10.1254/jphs.08042fp. View

19.

Nolin T, Frye R, Le P, Sadr H, Naud J, Leblond F . ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009; 20(10):2269-76. PMC: 2754095. DOI: 10.1681/ASN.2009010082. View

20.

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View